Verona Pharma Plc researches and develops drugs for the treatment of allergic rhinitis and other chronic respiratory diseases. It engages in discovering new drugs for the treatment of chronic respiratory diseases, such as asthma, allergic rhinitis, chronic obstructive pulmonary disease and cough. The company has three potential drug treatments: RPL554 is an innovative dual phosphodiesterase 3/4 inhibitor with both bronchodilator and anti-inflammatory properties. VRP700 is an innovative product for suppressing chronic severe cough in patients with underlying lung disease. With its third programme, the company is investigating novel anti-inflammatory molecules, called NAIPs, for a wide range of respiratory and inflammatory diseases. Verona Pharma was founded by Michael J. A. Walker in April 2004 and is headquartered in London, the United Kingdom.
Verona Pharma Plc
Alpha House 100 Borough High Street Suite 21
London, LO SE1 1LB
SIC Code: 2834